These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

697 related articles for article (PubMed ID: 18718471)

  • 1. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis.
    Aithal GP; Thomas JA; Kaye PV; Lawson A; Ryder SD; Spendlove I; Austin AS; Freeman JG; Morgan L; Webber J
    Gastroenterology; 2008 Oct; 135(4):1176-84. PubMed ID: 18718471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.
    Promrat K; Lutchman G; Uwaifo GI; Freedman RJ; Soza A; Heller T; Doo E; Ghany M; Premkumar A; Park Y; Liang TJ; Yanovski JA; Kleiner DE; Hoofnagle JH
    Hepatology; 2004 Jan; 39(1):188-96. PubMed ID: 14752837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial.
    Ratziu V; Giral P; Jacqueminet S; Charlotte F; Hartemann-Heurtier A; Serfaty L; Podevin P; Lacorte JM; Bernhardt C; Bruckert E; Grimaldi A; Poynard T;
    Gastroenterology; 2008 Jul; 135(1):100-10. PubMed ID: 18503774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis.
    Balas B; Belfort R; Harrison SA; Darland C; Finch J; Schenker S; Gastaldelli A; Cusi K
    J Hepatol; 2007 Oct; 47(4):565-70. PubMed ID: 17560678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.
    Neuschwander-Tetri BA; Brunt EM; Wehmeier KR; Oliver D; Bacon BR
    Hepatology; 2003 Oct; 38(4):1008-17. PubMed ID: 14512888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
    Belfort R; Harrison SA; Brown K; Darland C; Finch J; Hardies J; Balas B; Gastaldelli A; Tio F; Pulcini J; Berria R; Ma JZ; Dwivedi S; Havranek R; Fincke C; DeFronzo R; Bannayan GA; Schenker S; Cusi K
    N Engl J Med; 2006 Nov; 355(22):2297-307. PubMed ID: 17135584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis.
    Harrison SA; Torgerson S; Hayashi P; Ward J; Schenker S
    Am J Gastroenterol; 2003 Nov; 98(11):2485-90. PubMed ID: 14638353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
    Miyazaki Y; DeFronzo RA
    Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
    Bugianesi E; Gentilcore E; Manini R; Natale S; Vanni E; Villanova N; David E; Rizzetto M; Marchesini G
    Am J Gastroenterol; 2005 May; 100(5):1082-90. PubMed ID: 15842582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis.
    Idilman R; Mizrak D; Corapcioglu D; Bektas M; Doganay B; Sayki M; Coban S; Erden E; Soykan I; Emral R; Uysal AR; Ozden A
    Aliment Pharmacol Ther; 2008 Jul; 28(2):200-8. PubMed ID: 18445142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of peroxisome proliferator-activated receptor-gamma activation with pioglitazone on plasma adipokines in nondiabetic patients with either hypercholesterolemia or hypertension.
    Barac A; Campia U; Matuskey LA; Lu L; Panza JA
    Am J Cardiol; 2008 Apr; 101(7):980-5. PubMed ID: 18359318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.
    Nelson A; Torres DM; Morgan AE; Fincke C; Harrison SA
    J Clin Gastroenterol; 2009; 43(10):990-4. PubMed ID: 19448566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
    Tonstad S; Retterstøl K; Ose L; Ohman KP; Lindberg MB; Svensson M
    Metabolism; 2007 Sep; 56(9):1285-92. PubMed ID: 17697874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The effect of Cpd 861 on chronic hepatitis B related fibrosis and early cirrhosis: a randomized, double blind, placebo controlled clinical trial].
    Yin SS; Wang BE; Wang TL; Jia JD; Qian LX
    Zhonghua Gan Zang Bing Za Zhi; 2004 Aug; 12(8):467-70. PubMed ID: 15329205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis.
    Satapathy SK; Sakhuja P; Malhotra V; Sharma BC; Sarin SK
    J Gastroenterol Hepatol; 2007 May; 22(5):634-8. PubMed ID: 17444848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia.
    Hyogo H; Tazuma S; Arihiro K; Iwamoto K; Nabeshima Y; Inoue M; Ishitobi T; Nonaka M; Chayama K
    Metabolism; 2008 Dec; 57(12):1711-8. PubMed ID: 19013295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes.
    Bril F; Kalavalapalli S; Clark VC; Lomonaco R; Soldevila-Pico C; Liu IC; Orsak B; Tio F; Cusi K
    Clin Gastroenterol Hepatol; 2018 Apr; 16(4):558-566.e2. PubMed ID: 29223443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial.
    Torres DM; Jones FJ; Shaw JC; Williams CD; Ward JA; Harrison SA
    Hepatology; 2011 Nov; 54(5):1631-9. PubMed ID: 21748770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.
    Sanyal AJ; Campbell-Sargent C; Mirshahi F; Rizzo WB; Contos MJ; Sterling RK; Luketic VA; Shiffman ML; Clore JN
    Gastroenterology; 2001 Apr; 120(5):1183-92. PubMed ID: 11266382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease.
    Fernández-Miranda C; Pérez-Carreras M; Colina F; López-Alonso G; Vargas C; Solís-Herruzo JA
    Dig Liver Dis; 2008 Mar; 40(3):200-5. PubMed ID: 18261709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.